Vaccination of sheep with Maedi-visna virus gag gene and protein, beneficial or harmful?

Vaccine

Volumn 25, Issue 37-38, 2007, Pages 6713-6720

  Torsteinsdóttir, Sigurbjörg ^a   Carlsdóttir, Helga María ^a   Svansson, Vilhjálmur ^a   Matthíasdóttir, Sigrídur ^a   Martin, Agnes Helga ^a   Pétursson, Gudmundur ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

gag DNA vaccination; Maedi visna virus; Sheep

Indexed keywords

DNA VACCINE; GAG PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL STRAIN COS7; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG MECHANISM; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; SHEEP; VACCINATION; VIRUS ISOLATION; VISNA VIRUS; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, GAG; IMMUNIZATION; LYMPHOCYTES; SHEEP; TIME FACTORS; VACCINATION; VISNA-MAEDI VIRUS;

EID: 34548231041     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.004     Document Type: Article

References (50)

1. Sigurdsson B., Grimsson H., and Palsson P.A. Maedi, a chronic, progressive infection of sheep's lungs. J Infect Dis 90 3 (1952) 233-241
2. Sigurdsson B., Palsson P., and Grimsson H. Visna, a demyelinating transmissible disease of sheep. J Neuropathol Exp Neurol 16 3 (1957) 389-403
3. Gendelman H.E., Narayan O., Kennedy-Stoskopf S., Kennedy P.G., Ghotbi Z., Clements J.E., et al. Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages. J Virol 58 1 (1986) 67-74
4. Gorrell M.D., Brandon M.R., Sheffer D., Adams R.J., and Narayan O. Ovine lentivirus is macrophagetropic and does not replicate productively in T lymphocytes. J Virol 66 5 (1992) 2679-2688
5. Sigurdsson B. Observations on three slow infections of sheep (1). Br Vet J 110 (1954) 255-270
6. Audoly G., Sauze N., Harkiss G., Vitu C., Russo P., Querat G., et al. Identification and subcellular localization of the Q gene product of visna virus. Virology 189 2 (1992) 734-739
7. Gourdou I., Mazarin V., Querat G., Sauze N., and Vigne R. The open reading frame S of visna virus genome is a trans-activating gene. Virology 171 1 (1989) 170-178
8. Kristbjornsdottir H.B., Andresdottir V., Svansson V., Torsteinsdottir S., Matthiasdottir S., and Andresson O.S. The vif gene of maedi-visna virus is essential for infectivity in vivo and in vitro. Virology 318 1 (2004) 350-359
9. Sargan D.R., and Bennet I.D. A transcriptional map of visna virus: definition of the second intron structure suggests a rev-like gene product. J Gen Virol 70 Pt 8 (1989) 1995-2006
10. Tiley L.S., Brown P.H., Le S.Y., Maizel J.V., Clements J.E., and Cullen B.R. Visna virus encodes a post-transcriptional regulator of viral structural gene expression. Proc Natl Acad Sci USA 87 19 (1990) 7497-7501
11. Vigne R., Filippi P., Querat G., Sauze N., Vitu C., Russo P., et al. Precursor polypeptides to structural proteins of visna virus. J Virol 42 3 (1982) 1046-1056
12. Torsteinsdóttir S., Andrésdóttir V., Arnarson H., and Pétursson G. Immune response to maedi-visna virus. Front Biol 12 (2007) 1532-1543
13. Petursson G., Matthiasdottir S., Svansson V., Andresdottir V., Georgsson G., Martin A.H., et al. Mucosal vaccination with an attenuated maedi-visna virus clone. Vaccine 23 24 (2005) 3223-3228
14. Gonzalez B., Reina R., Garcia I., Andres S., Glaria I., Alzueta M., et al. Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection. Vaccine 23 34 (2005) 4342-4352
15. Andresson O.S., Elser J.E., Tobin G.J., Greenwood J.D., Gonda M.A., Georgsson G., et al. Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus. Virology 193 1 (1993) 89-105
16. Skraban R., Matthiasdottir S., Torsteinsdottir S., Agnarsdottir G., Gudmundsson B., Georgsson G., et al. Naturally occurring mutations within 39 amino acids in the envelope glycoprotein of maedi-visna virus alter the neutralization phenotype. J Virol 73 10 (1999) 8064-8072
17. Rafnar B., Tobin G.J., Nagashima K., Gonda M.A., Gunnarsson E., Andresson O.S., et al. Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells. Virus Res 53 2 (1998) 107-120
18. Torsteinsdottir S., Matthiasdottir S., Vidarsdottir N., Svansson V., and Petursson G. Intratracheal inoculation as an efficient route of experimental infection with maedi-visna virus. Res Vet Sci 75 3 (2003) 245-247
19. Torsteinsdottir S., Agnarsdottir G., Matthiasdottir S., Rafnar B., Andresdottir V., Andresson O.S., et al. In vivo and in vitro infection with two different molecular clones of visna virus. Virology 229 2 (1997) 370-380
20. Torsteinsdottir S., Georgsson G., Gisladottir E., Rafnar B., Palsson P.A., and Petursson G. Pathogenesis of central nervous system lesions in visna: cell-mediated immunity and lymphocyte subsets in blood, brain and cerebrospinal fluid. J Neuroimmunol 41 2 (1992) 149-158
21. Houwers D.J., Gielkens A.L., and Schaake Jr. J. An indirect enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to maedi-visna virus. Vet Microbiol 7 3 (1982) 209-219
22. Petursson G., Nathanson N., Georgsson G., Panitch H., and Palsson P.A. Pathogenesis of visna. I. Sequential virologic, serologic, and pathologic studies. Lab Invest 35 4 (1976) 402-412
23. Tiley L.S., and Cullen B.R. Structural and functional analysis of the visna virus Rev-response element. J Virol 66 6 (1992) 3609-3615
24. Bray M., Prasad S., Dubay J.W., Hunter E., Jeang K.T., Rekosh D., et al. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci USA 91 4 (1994) 1256-1260
25. Palsson P.A. Maedi and visna in sheep. Front Biol 44 (1976) 17-43
26. Blacklaws B.A., Berriatua E., Torsteinsdottir S., Watt N.J., de Andres D., Klein D., et al. Transmission of small ruminant lentiviruses. Vet Microbiol 101 3 (2004) 199-208
27. Eriksson K., McInnes E., Ryan S., Tonks P., McConnell I., and Blacklaws B. CD4(+) T-cells are required for the establishment of maedi-visna virus infection in macrophages but not dendritic cells in vivo. Virology 258 2 (1999) 355-364
28. Nathanson N., Martin J.R., Georgsson G., Palsson P.A., Lutley R.E., and Petursson G. The effect of post-infection immunization on the severity of experimental visna. J Comp Pathol 91 2 (1981) 185-191
29. Nathanson N., Panitch H., Palsson P.A., Petursson G., and Georgsson G. Pathogenesis of visna. II. Effect of immunosuppression upon early central nervous system lesions. Lab Invest 35 5 (1976) 444-451
30. Cutlip R.C., Lehmkuhl H.D., Brogden K.A., and Schmerr M.J. Failure of experimental vaccines to protect against infection with ovine progressive pneumonia (maedi-visna) virus. Vet Microbiol 13 3 (1987) 201-204
31. Petursson G., Palsson P.A., and Georgsson G. Maedi-visna in sheep: host-virus interactions and utilization as a model. Intervirology 30 Suppl. 1 (1989) 36-44
32. Valas S., Benoit C., Guionaud C., Perrin G., and Mamoun R.Z. North American and French caprine arthritis-encephalitis viruses emerge from ovine maedi-visna viruses. Virology 237 2 (1997) 307-318
33. Rolland M., Mooney J., Valas S., Perrin G., and Mamoun R.Z. Characterisation of an Irish caprine lentivirus strain-SRLV phylogeny revisited. Virus Res 85 1 (2002) 29-39
34. Harmache A., Vitu C., Guiguen F., Russo P., Bertoni G., Pepin M., et al. Priming with tat-deleted caprine arthritis encephalitis virus (CAEV) proviral DNA or live virus protects goats from challenge with pathogenic CAEV. J Virol 72 8 (1998) 6796-6804
35. Beyer J.C., Chebloune Y., Mselli-Lakhal L., Hotzel I., Kumpula-McWhirter N., and Cheevers W.P. Immunization with plasmid DNA expressing the caprine arthritis-encephalitis virus envelope gene: quantitative and qualitative aspects of antibody response to viral surface glycoprotein. Vaccine 19 13-14 (2001) 1643-1651
36. Cheevers W.P., Snekvik K.R., Trujillo J.D., Kumpula-McWhirter N.M., Pretty On Top K.J., and Knowles D.P. Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and viral SU suppresses challenge virus and development of arthritis. Virology 306 1 (2003) 116-125
37. McGuire T.C., Adams D.S., Johnson G.C., Klevjer-Anderson P., Barbee D.D., and Gorham J.R. Acute arthritis in caprine arthritis-encephalitis virus challenge exposure of vaccinated or persistently infected goats. Am J Vet Res 47 3 (1986) 537-540
38. Nenci C., Zahno M.L., Vogt H.R., Obexer-Ruff G., Doherr M.G., Zanoni R., et al. Vaccination with a T-cell-priming Gag peptide of caprine arthritis encephalitis virus enhances virus replication transiently in vivo. J Gen Virol 88 Pt 5 (2007) 1589-1593
39. Uhl E.W., Heaton-Jones T.G., Pu R., and Yamamoto J.K. FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review. Vet Immunol Immunopathol 90 3-4 (2002) 113-132
40. Yamamoto J.K., Hohdatsu T., Olmsted R.A., Pu R., Louie H., Zochlinski H.A., et al. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol 67 1 (1993) 601-605
41. Dunham S.P. Lessons from the cat: development of vaccines against lentiviruses. Vet Immunol Immunopathol 112 1-2 (2006) 67-77
42. Hosie M.J., Osborne R., Reid G., Neil J.C., and Jarrett O. Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol 35 1-2 (1992) 191-197
43. Karlas J.A., Siebelink K.H., Peer M.A., Huisman W., Cuisinier A.M., Rimmelzwaan G.F., et al. Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol 80 Pt 3 (1999) 761-765
44. Siebelink K.H., Tijhaar E., Huisman R.C., Huisman W., de Ronde A., Darby I.H., et al. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 69 6 (1995) 3704-3711
45. Richardson J., Broche S., Baud S., Leste-Lasserre T., Femenia F., Levy D., et al. Lymphoid activation: a confounding factor in AIDS vaccine development?. J Gen Virol 83 Pt 10 (2002) 2515-2521
46. Richardson J., Moraillon A., Baud S., Cuisinier A.M., Sonigo P., and Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 71 12 (1997) 9640-9649
47. Wang S.Z., Rushlow K.E., Issel C.J., Cook R.F., Cook S.J., Raabe M.L., et al. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199 1 (1994) 247-251
48. Raabe M.L., Issel C.J., Cook S.J., Cook R.F., Woodson B., and Montelaro R.C. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology 245 1 (1998) 151-162
49. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 101 35 (2004) 13026-13031
50. Fust G. Enhancing antibodies in HIV infection. Parasitology 115 Suppl. (1997) S127-S140